NP/PA Connect
News
Media
Around the PracticeBetween The LinesCase-Based Peer PerspectiveClinical Case CollectiveDermViewExpert PerspectivesFellows Face OffFrontline ForumMedical World NewsPatient PerspectivesPodcastsReadout360Recognize and Refer
Conferences
Conference CoverageConference Listing
Events
Case-Based Roundtable
More
Publication
Dermatology Times
CME/CE
Resources
DermIQInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • NP/PA Connect
  • News
  • Media
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Non-Melanoma Skin Cancers
  • Vitiligo
  • Wound Care
Advertisement

Loretta Fiorillo, MD, FRCPC

Advertisement

Articles by Loretta Fiorillo, MD, FRCPC

Apremilast Demonstrates Consistent Safety and Efficacy in Children with Moderate to Severe Plaque Psoriasis at 52 Weeks

ByKaitlyn Bader, Senior Editor ,Loretta Fiorillo, MD, FRCPC
April 9th 2024

Loretta Fiorillo, MD, FRCPC, reviews key data points from the phase 3 SPROUT study.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Dermatology Times

    1

    Delgocitinib Advances to Phase 3 Evaluation for Lichen Sclerosus

    2

    The Aesthetic Edge: January 2026

    3

    Case-Based Perspectives on Biologic Treatment for Hidradenitis Suppurativa

    4

    LEVEL UP Study Shows Benefits of Switching From Dupilumab to Upadacitinib in AD

    5

    Atopia Therapeutics Reports Positive Preclinical Data for ATP-R13 as Disease-Modifying Oral AD Therapy

    • About
    • Advertise
    • Contact Us
    • Job Board
    • Do Not Sell My Information
    • Terms and Conditions
    • Privacy Policy
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us